Literature DB >> 17631069

Effects of heart failure and diabetes mellitus on long-term mortality after coronary revascularization (from the BARI Trial).

Elizabeth M Holper1, Maria Mori Brooks, Lauren J Kim, Katherine M Detre, David P Faxon.   

Abstract

This study evaluated the effect of heart failure (HF) and ejection fraction (EF) at baseline on long-term cardiac mortality in patients undergoing coronary revascularization and investigated the effect of diabetes mellitus (DM) on mortality. We evaluated long-term outcomes of patients without HF, HF and a preserved EF, and HF and a decreased EF who underwent revascularization with percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery after enrollment in the Bypass Angioplasty Revascularization Investigation (BARI) trial. Ten years after initial revascularization, cumulative rates of freedom from cardiac death were 90% in patients without HF, 75% in patients with HF and a preserved EF, and 59% in patients with HF and a decreased EF (p <0.001, 3-way comparison). In diabetic patients with HF and a preserved EF, there was a significant increase in cardiac mortality compared with patients without HF (p <0.001); however, this relation was not seen in patients without DM. In conclusion, patients with HF and a preserved EF have increased mortality over 10 years compared with those without HF. Only in patients with DM did HF with preserved EF confer additional risk.

Entities:  

Mesh:

Year:  2007        PMID: 17631069     DOI: 10.1016/j.amjcard.2007.02.082

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  1 in total

1.  Comparing clinical outcomes in patients with diabetes undergoing coronary artery bypass graft and percutaneous coronary intervention in real world practice in Iranian population.

Authors:  Arezo Arabi; Behshad Naghshtabrizi; Hamid Reza Baradaran; Yousef Moradi; Mohsen Asadi-Lari; Ali Mehrakizadeh
Journal:  BMC Cardiovasc Disord       Date:  2022-03-03       Impact factor: 2.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.